Results 201 to 210 of about 1,081,556 (334)
Public Choice, Constitutional Political Economy and Law and Economics [PDF]
The various subdisciplines within the emerging ‘new institutionalism’ in economics all draw special attention to the legal-political constraints within which economic and political agents choose and therefore represent a return of economics to its ...
Ludwig van den Hauwe
core
British Journal of Clinical Pharmacology, EarlyView.Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló +5 more
wiley +1 more source
Can government-guided funds promote innovation output in strategic emerging enterprises? Evidence from China. [PDF]
PLoS OneZhao C, Zhang L.
europepmc +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria
British Journal of Clinical Pharmacology, EarlyView.Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova +5 more
wiley +1 more source
Research on the U-shaped relationship between marketization process and corporate capital structure: Evidence from Chinese listed companies. [PDF]
PLoS OneXu J, Zhang L.
europepmc +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang +6 more
wiley +1 more source
FOUNDATIONS OF CONTEMPORARY ECONOMICS: NEW INSTITUTIONAL ECONOMICS VS. NEW ECONOMIC SOCIOLOGY – THE GRANOVETTER-WILLIAMSON DEBATE [PDF]
Henrik Egbert +2 more
openalex +1 more source
Contracts and Transaction Costs in New Institutional Economics [PDF]
, 2005 Katarzyna Kowalska
openalex +1 more source